CN104508149A - 对jak/stat抑制剂治疗响应的预测 - Google Patents

对jak/stat抑制剂治疗响应的预测 Download PDF

Info

Publication number
CN104508149A
CN104508149A CN201380040005.0A CN201380040005A CN104508149A CN 104508149 A CN104508149 A CN 104508149A CN 201380040005 A CN201380040005 A CN 201380040005A CN 104508149 A CN104508149 A CN 104508149A
Authority
CN
China
Prior art keywords
jak
biomarker
stat
inhibitor
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380040005.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·曹
M·莫里西
D·桑金
M·帕尔玛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48906529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104508149(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104508149A publication Critical patent/CN104508149A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201380040005.0A 2012-07-27 2013-07-24 对jak/stat抑制剂治疗响应的预测 Pending CN104508149A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261676484P 2012-07-27 2012-07-27
US61/676,484 2012-07-27
US201361769271P 2013-02-26 2013-02-26
US61/769,271 2013-02-26
US201361829327P 2013-05-31 2013-05-31
US61/829,327 2013-05-31
PCT/US2013/051824 WO2014018632A1 (en) 2012-07-27 2013-07-24 Prediction of treatment response to jak/stat inhibitor

Publications (1)

Publication Number Publication Date
CN104508149A true CN104508149A (zh) 2015-04-08

Family

ID=48906529

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380040005.0A Pending CN104508149A (zh) 2012-07-27 2013-07-24 对jak/stat抑制剂治疗响应的预测

Country Status (18)

Country Link
US (1) US20150299796A1 (https=)
EP (1) EP2877596A1 (https=)
JP (1) JP2015526074A (https=)
KR (1) KR20150038241A (https=)
CN (1) CN104508149A (https=)
AU (2) AU2013295855A1 (https=)
BR (1) BR112015001521A2 (https=)
CA (1) CA2880198A1 (https=)
CL (1) CL2015000192A1 (https=)
HK (1) HK1205198A1 (https=)
IL (1) IL236897A0 (https=)
MX (1) MX2015001269A (https=)
PH (1) PH12015500169A1 (https=)
RU (1) RU2015106714A (https=)
SG (1) SG11201500261VA (https=)
TN (1) TN2015000019A1 (https=)
TW (1) TW201409030A (https=)
WO (1) WO2014018632A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106544414A (zh) * 2016-10-09 2017-03-29 广州泰诺迪生物科技有限公司 一种检测肺癌脑转移样本中stat3和lck的方法
CN107137701A (zh) * 2017-05-07 2017-09-08 南京盖斯夫医药科技有限公司 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083705A1 (en) * 2001-04-13 2002-10-24 The Johns Hopkins University School Of Medicine Socs-1 gene methylation in cancer
WO2012071612A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
WO2010048123A2 (en) * 2008-10-20 2010-04-29 Eckhardt S Gail Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CN102459258B (zh) * 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083705A1 (en) * 2001-04-13 2002-10-24 The Johns Hopkins University School Of Medicine Socs-1 gene methylation in cancer
WO2012071612A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIANA ABDUEVA 等: "Experimental Comparison and Evaluation of the Affymetrix Exon and U133Plus2 GeneChip Arrays", 《PLOS ONE》 *
TAGHI MANSHOURI 等: "Ruxolitinib, a Janus Kinase (JAK)-1 and -2 Inhibitor Modulates Microrna (miR)Levels in Patients with Myelofibrosis (MF): miR Levels Might Predict MF Treatment Outcome", 《BLOOD》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106544414A (zh) * 2016-10-09 2017-03-29 广州泰诺迪生物科技有限公司 一种检测肺癌脑转移样本中stat3和lck的方法
CN107137701A (zh) * 2017-05-07 2017-09-08 南京盖斯夫医药科技有限公司 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗
CN107137701B (zh) * 2017-05-07 2020-07-14 山东兴瑞生物科技有限公司 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗

Also Published As

Publication number Publication date
JP2015526074A (ja) 2015-09-10
RU2015106714A (ru) 2016-09-20
CL2015000192A1 (es) 2015-06-26
MX2015001269A (es) 2015-05-08
IL236897A0 (en) 2015-03-31
TN2015000019A1 (en) 2016-06-29
KR20150038241A (ko) 2015-04-08
US20150299796A1 (en) 2015-10-22
AU2013295855A1 (en) 2015-02-12
PH12015500169A1 (en) 2015-03-16
EP2877596A1 (en) 2015-06-03
WO2014018632A1 (en) 2014-01-30
BR112015001521A2 (pt) 2017-11-07
SG11201500261VA (en) 2015-02-27
AU2017204894A1 (en) 2017-08-03
CA2880198A1 (en) 2014-01-30
TW201409030A (zh) 2014-03-01
HK1205198A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
CN104508149A (zh) 对jak/stat抑制剂治疗响应的预测
Ranade et al. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer
EP2715366B1 (en) Biomarkers for hedgehog inhibitor therapy
Ricarte-Filho et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1
EP3458604B1 (en) Method for determining sensitivity to a cdk4/6 inhibitor
EP2711433B1 (en) Method for predicting effectiveness of angiogenesis inhibitor
CN118813801A (zh) 大肠癌的检测试剂盒或装置以及检测方法
CN117965741A (zh) 胰腺癌的检测试剂盒或装置以及检测方法
CN103261413B (zh) 三剂并用抗癌剂感受性判定标记
CN119220676A (zh) 前列腺癌的检测试剂盒或装置以及检测方法
Choi et al. MicroRNA expression profile of gastrointestinal stromal tumors is distinguished by 14q loss and anatomic site
CN105102983B (zh) Ddr2突变作为黑素瘤或基底细胞癌的可靶向的特征
CA2504403A1 (en) Prognostic for hematological malignancy
JP6513019B2 (ja) Ｉａｐインヒビター治療のためのバイオマーカー
Pfeffer Cancer genomics: molecular classification, prognosis and response prediction
CN111433375A (zh) 选择针对癌症患者的治疗的方法
KR20230087445A (ko) Aml의 치료 요법 및 rara 작용제, 저메틸화제, 및 bcl-2 억제제의 용도
EP3321377A1 (en) Method for determining sensitivity to simultaneous inhibitor against parp and tankyrase
WO2010076887A1 (en) Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
JP7610265B2 (ja) 大腸癌診断用マーカー、大腸癌の診断を補助する方法、大腸癌の診断のためにデータを収集する方法、大腸癌の診断用キット、大腸癌治療薬、大腸癌の治療方法、大腸癌の診断方法
KR101869931B1 (ko) 표적 항암 치료제에 대한 감수성 예측 방법
WO2010073721A1 (ja) ＭｉｃｒｏＲＮＡによる直腸癌に対する術前化学放射線療法の効果予測
Hur et al. Gene expression profiling of human gastrointestinal stromal tumors according to its malignant potential
US20120157342A1 (en) Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
US20100015620A1 (en) Cancer-linked genes as biomarkers to monitor response to impdh inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150408